[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].

The susceptibility has been determined of 169 Shigella spp., 93 Salmonella spp., 68 Yersinia enterocolitica, 34 Vibrio cholerae 0:1, and 34 Campylobacter jejuni, isolated in Central Africa and in Belgium, to ten fluoroquinolones: ciprofloxacin, ofloxacin, norfloxacin, pefloxacin, enoxacin, amifloxacin, CI-934, A-56619, A-56620 and RO 23-6240.

Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.

A severe epidemic of dysentery began late in 1979 in northeast Zaire and spread to Rwanda, Burundi, and Tanzania. The epidemic strain is a multiply resistant Shigella dysenteriae type 1, which acquired resistance against trimethoprim and more recently against nalidixic acid in the course of the epidemic. A comparative open trial in Rwandan adults with Shiga dysentery involved 18 patients treated with norfloxacin at 400 mg twice daily and 12 patients treated with nalidixic acid at 1 g three times daily for 5 days.